Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 to 2019 with sites across 5 continents, REPRIEVE will assess the effects of a statin as a cardiovascular disease pre...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Infect Dis
Egile Nagusiak: Grinspoon, Steven K, Douglas, Pamela S, Hoffmann, Udo, Ribaudo, Heather J
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Supplement Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7347079/
https://ncbi.nlm.nih.gov/pubmed/32645161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiaa098
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak